Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors

Neurobiology of Disease

Volumn 47, Issue 2, 2012, Pages 268-279

  Villar Cheda, Begoña ^a,b   Dominguez Meijide, Antonio ^a,b   Joglar, Belen ^a,b   Rodriguez Perez, Ana I ^a,b   Guerra, Maria J ^a,b   Labandeira Garcia, Jose L ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Angiotensin; Dopamine; Neurodegeneration; Neuroinflammation; Neuroprotection; Neurotoxins; Parkinson; Rho; Rho kinase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; NEUROTOXIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE DELETION; MALE; MESENCEPHALON; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

AMIDES; ANGIOTENSINS; ANIMALS; CELL DEATH; CELLS, CULTURED; DOPAMINERGIC NEURONS; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84861703950     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.04.010     Document Type: Article

References (77)

1. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 2004, 16:42-47.
2. Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., Inzitari D. Parkinson's disease and Parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian longitudinal study on aging. Neurology 2000, 55:1358-1363.
3. Basso N., Paglia N., Stella I., de Cavanagh E.M., Ferder L., del Rosario Lores Arnaiz M., Inserra F. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul. Pept. 2005, 128:247-252.
4. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L., Cassis P., Morigi M., Coffman T.M., Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 2009, 119:524-530.
5. Bernhart E., Kollroser M., Rechberger G., Reicher H., Heinemann A., Schratl P., Hallström S., Wintersperger A., Nusshold C., DeVaney T., Zorn-Pauly K., Malli R., Graier W., Malle E., Sattler W. Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics 2010, 10:141-158.
6. Biber K., Neumann H., Inoue K., Boddeke H.W. Neuronal 'on' and 'off' signals control microglia. Trends Neurosci. 2007, 30:596-602.
7. Budzyn K., Marley P.D., Sobey C.G. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol. Sci. 2006, 27:97-104.
8. Büyükafşar K., Yalçin I., Kurt A.H., Tiftik R.N., Sahan-Firat S., Aksu F. Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice. Eur. J. Pharmacol. 2006, 541:49-52.
9. Cai H., Griendling K.K., Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 2003, 24:471-478.
10. Chabrashvili T., Kitiyakara C., Blau J., Karber A., Aslam S., Welch W.J., Wilcox C.S. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R117-R124.
11. de Cavanagh E.M., Inserra F., Ferder L. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?. Cardiovasc. Res. 2011, 89:31-40.
12. Diamond S.G., Markham C.H., Hoehn M.M., McDowell F.H., Muenter M.D. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990, 40:763-766.
13. Dikalova A.E., Bikineyeva A.T., Budzyn K., Nazarewicz R.R., McCann L., Lewis W., Harrison D.G., Dikalov S.I. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ. Res. 2010, 107:106-116.
14. Doughan A.K., Harrison D.G., Dikalov S.I. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ. Res. 2008, 102:488-496.
15. Gao H.M., Liu B., Zhang W., Hong J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 2003, 17:1954-1956.
16. Gao H.M., Liu B., Zhang W., Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J. 2003, 17:1957-1959.
17. Gao X., Hu X., Qian L., Yang S., Zhang W., Zhang D., Wu X., Fraser A., Wilson B., Flood P.M., Block M., Hong J.S. Formyl-methionyl-leucyl-phenylalanine-induced dopaminergic neurotoxicity via microglial activation: a mediator between peripheral infection and neurodegeneration?. Environ. Health Perspect. 2008, 116:593-598.
18. González-Hernández T., Cruz-Muros I., Afonso-Oramas D., Salas-Hernandez J., Castro-Hernandez J. Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. Front. Neuroanat. 2010, 4:140.
19. Grammatopoulos T.N., Jones S.M., Ahmadi F.A., Hoover B.R., Snell L.D., Skoch J., Jhaveri V.V., Poczobutt A.M., Weyhenmeyer J.A., Zawada W.M. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2007, 2:1.
20. Greenwood J., Walters C.E., Pryce G., Kanuga N., Beraud E., Baker D., Adamson P. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003, 17:905-907.
21. Gundersen H.J., Bendtsen T.F., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., Sorensen F.B., Vesterby A., West M.J. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988, 96:379-394.
22. Hiroki J., Shimokawa H., Higashi M., Morikawa K., Kandabashi T., Kawamura N., Kubota T., Ichiki T., Amano M., Kaibuchi K., Takeshita A. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J. Mol. Cell. Cardiol. 2004, 37:537-546.
23. Hiroki J., Shimokawa H., Mukai Y., Ichiki T., Takeshita A. Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2005, 326:154-159.
24. Honing H., van den Berg T.K., van der Pol S.M., Dijkstra C.D., van der Kammen R.A., Collard J.G., de Vries H.E. RhoA activation promotes transendothelial migration of monocytes via ROCK. J. Leukoc. Biol. 2004, 75:523-528.
25. +) in brain tissue homogenates. J. Neurosci. Methods 2004, 137:221-226.
26. Iida H., Iida M., Takenaka M., Fukuoka N., Dohi S. Rho-kinase inhibitor and nicotinamide adenine dinucleotide phosphate oxidase inhibitor prevent impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking in rats. J. Renin Angiotensin Aldosterone Syst. 2008, 9:89-94.
27. Ito K., Hirooka Y., Kimura Y., Sagara Y., Sunagawa K. Ovariectomy augments hypertension through rho-kinase activation in the brain stem in female spontaneously hypertensive rats. Hypertension 2006, 48:651-657.
28. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
29. Joglar B., Rodriguez-Pallares J., Rodriguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 2009, 109:656-669.
30. Jones E.S., Vinh A., McCarthy C.A., Gaspari T.A., Widdop R.E. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol. Ther. 2008, 120:292-316.
31. Katoh H., Aoki J., Ichikawa A., Negishi M. p160 RhoA-binding kinase ROKalpha induces neurite retraction. J. Biol. Chem. 1998, 273:2489-2492.
32. Kimura S., Zhang G.X., Nishiyama A., Shokoji T., Yao L., Fan Y.Y., Rahman M., Suzuki T., Maeta H., Abe Y. Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005, 45:860-866.
33. Kume T., Ito R., Taguchi R., Izumi Y., Katsuki H., Niidome T., Takada-Takatori Y., Sugimoto H., Akaike A. Serofendic acid promotes stellation induced by cAMP and cGMP analogs in cultured cortical astrocytes. J. Pharmacol. Sci. 2009, 109:110-118.
34. Labandeira-Garcia J.L., Rodriguez-Pallares J., Villar-Cheda B., Rodríguez-Perez A.I., Garrido-Gil P., Guerra M.J. Aging, angiotensin system and dopaminergic degeneration in the substantia nigra. Aging Dis. 2011, 2:257-274.
35. Lanz T.V., Ding Z., Ho P.P., Luo J., Agrawal A.N., Srinagesh H., Axtell R., Zhang H., Platten M., Wyss-Coray T., Steinman L. Angiotensin II sustains brain inflammation in mice via TGF-beta. J. Clin. Invest. 2010, 120:2782-2794.
36. Li Q., Liu H., Du J., Chen B., Li Q., Guo X., Huang X., Huang Q. Advanced glycation end products induce moesin phosphorylation in murine brain endothelium. Brain Res. 2011, 1373:1-10.
37. Lopez-Real A., Rey P., Soto-Otero R., Mendez-Alvarez E., Labandeira-Garcia J.L. Angiotensin-converting enzyme inhibitors reduce oxidative stress and protect dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J. Neurosci. Res. 2005, 81:865-873.
38. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
39. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A., Chai S.Y. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol. 2003, 35:901-918.
40. Mueller B.K., Mack H., Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 2005, 4:387-398.
41. Muñoz A., Rey P., Guerra M.J., Mendez-Alvarez E., Soto-Otero R., Labandeira-Garcia J.L. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of Parkinsonism. Neuropharmacology 2006, 51:112-120.
42. Nakagawa O., Fujisawa K., Ishizaki T., Saito Y., Nakao K., Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996, 392:189-193.
43. Ohtsu H., Suzuki H., Nakashima H., Dhobale S., Frank G.D., Motley E.D., Eguchi S. Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension 2006, 48:534-540.
44. Pacary E., Legros H., Valable S., Duchatelle P., Lecocq M., Petit E., Nicole O., Bernaudin M. Synergistic effects of CoCl(2) and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells. J. Cell Sci. 2006, 119:2667-2678.
45. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:4565-4571.
46. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 2004, 279:1415-1421.
47. Rey P., Lopez-Real A., Sanchez-Iglesias S., Muñoz A., Soto-Otero R., Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 2007, 28:555-567.
48. Rodriguez-Pallares J., Parga J.A., Muñoz A., Rey P., Guerra M.J., Labandeira-Garcia J.L. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J. Neurochem. 2007, 103:145-156.
49. Rodriguez-Pallares J., Rey P., Parga J.A., Muñoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
50. Rodriguez-Pallares J., Parga J.A., Joglar B., Guerra M.J., Labandeira-Garcia J.L. The mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons. Neurotox. Res. 2009, 15:82-95.
51. Rodriguez-Pallares J., Parga J.A., Joglar B., Guerra M.J., Labandeira-Garcia J.L. Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease. Age (Dordr.) 2011, (Electronic publication ahead of print) (PMID:21713375).
52. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Lanciego J.L., Labandeira-Garcia J.L. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease. Exp. Neurol. 2010, 224:517-526.
53. Rodriguez-Perez A.I., Valenzuela R., Joglar B., Garrido-Gil P., Guerra M.J., Labandeira-Garcia J.L. Renin angiotensin system and gender differences in dopaminergic degeneration. Mol. Neurodegener. 2011, 6:58.
54. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Labandeira-Garcia J.L. Different dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats. Role of the brain angiotensin system. Brain 2012, 135:124-138.
55. Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., Suzuki Y., Mezzano S., Plaza J.J., Egido J. Role of the renin-angiotensin system in vascular diseases. Expanding the field. Hypertension 2001, 38:1382-1387.
56. Saavedra J.M. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell. Mol. Neurobiol. 2005, 25:485-512.
57. Schmandke A., Schmandke A., Strittmatter S.M. ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist 2007, 13:454-469.
58. Seshiah P.N., Weber D.S., Rocic P., Valppu L., Taniyama Y., Griendling K.K. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 2002, 91:406-413.
59. Sheikh A.M., Nagai A., Ryu J.K., McLarnon J.G., Kim S.U., Masuda J. Lysophosphatidylcholine induces glial cell activation: role of rho kinase. Glia 2009, 57:898-907.
60. Sohn H.Y., Raff U., Hoffmann A., Gloe T., Heermeier K., Galle J., Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br. J. Pharmacol. 2000, 131:667-672.
61. Song J., Kost C.K., Martin D.S. Androgens potentiate renal vascular responses to angiotensin II via amplification of the Rho kinase signaling pathway. Cardiovasc. Res. 2006, 72:456-463.
62. Stegbauer J., Lee D.H., Seubert S., Ellrichmann G., Manzel A., Kvakan H., Muller D.N., Gaupp S., Rump L.C., Gold R., Linker R.A. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14942-14947.
63. Sugaya T., Nishimatsu S., Tanimoto K., Takimoto E., Yamagishi T., Imamura K., Goto S., Imaizumi K., Hisada Y., Otsuka A., Sugiura M., Fukuta K., Fukamizu A., Murakami K. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 1995, 270:18719-18722.
64. Suzuki Y., Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., Egido J. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 2003, 35:881-900.
65. Torres E.M., Meldrum A., Kirik D., Dunnett S.B. An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections. J. Neurosci. Methods 2006, 158:64-74.
66. Toshima Y., Satoh S., Ikegaki I., Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000, 31:2245-2250.
67. Touyz R.M., Chen X., Tabet F., Yao G., He G., Quinn M.T., Pagano P.J., Schiffrin E.L. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 2002, 90:1205-1213.
68. Valenzuela R., Barroso-Chinea P., Villar-Cheda B., Joglar B., Muñoz A., Lanciego J.L., Labandeira-Garcia J.L. Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death. J. Neuropathol. Exp. Neurol. 2010, 69:1130-1142.
69. Villar-Cheda B., Rodríguez-Pallares J., Muñoz A., Valenzuela R., Guerra M.J., Baltatu O.C., Labandeira-Garcia J.L. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease. Eur. J. Neurosci. 2010, 32:1695-1706.
70. Villar-Cheda B., Valenzuela R., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol. Aging 2012, 33:204.e1-204.e11.
71. Wosniak J., Santos C.X., Kowaltowski A.J., Laurindo F.R. Cross-talk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. Antioxid. Redox. Signal. 2009, 11:1265-1278.
72. Wu D., Teisman P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsonr̈s disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6145-6150.
73. Yan J., Zhou X., Guo J.J., Mao L., Wang Y.J., Sun J., Sun L.X., Zhang L.Y., Zhou X.F., Liao H. Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro. J. Neurochem. 2012, 120:721-731.
74. Zawada W.M., Banninger G.P., Thornton J., Marriott B., Cantu D., Rachubinski A.L., Das M., Griffin W.S., Jones S.M. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J. Neuroinflammation 2011, 8:129.
75. Zhang Y., Gu X., Yuan X. Phenylalanine activates the mitochondria-mediated apoptosis through the RhoA/Rho-associated kinase pathway in cortical neurons. Eur. J. Neurosci. 2007, 25:1341-1348.
76. Zhou C., Huang Y., Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N. Y. Acad. Sci. 2008, 1147:93-104.
77. Zohrabian V.M., Forzani B., Chau Z., Murali R., Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer. Res. 2009, 29:119-123.